BioNTech SE (BNTX)

Sep 28, 2026

This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline. The piece aims to determine which company offers a more attractive long-term setup for investors.

Sep 27, 2026

BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA‑4 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline. While COVID-19 vaccine revenue provides short-term cash flow, the company is heavily investing in oncology to secure long-term profitability, despite risks of prolonged losses and delayed approvals.

Sep 22, 2026

BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The outlook remains bullish as long as support at $95.30 holds, with an expected target of $105.50 for its first resistance level.

Sep 22, 2026

BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.

Sep 22, 2026

BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious diseases. While financial metrics suggest caution, analyst ratings remain optimistic, highlighting a balance between innovative potential and financial health for investors.

Sep 14, 2026

BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy. Results from the PRESERVE-003 Phase 3 clinical trial showed that gotistobart nearly doubled survival compared to standard-of-care chemotherapy. This marks a clinically meaningful benefit for a specific type of lung cancer.